Next 10 |
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In GoodRx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 28, 2024) - Faruqi & Faruqi, LLP, a leading national s...
Do you, or did you, own shares of GoodRx Holdings, Inc. (NASDAQ: GDRX)? Did you purchase your shares between September 23, 2020 and November 8, 2022, inclusive? Did you lose money in your investment in GoodRx Holdings, Inc.? Do you want to discuss your rights? NEW YORK, NY / A...
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings in the U.S., today announced it will hold its first Investor Day on May 15, 2024, in New York City. The event will begin at 9:00 a.m. Eastern Time (6:00...
NEW YORK, NY / ACCESSWIRE / April 24, 2024 / Bernstein Liebhard LLP: Do you, or did you, own shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)? Did you purchase your shares between September 23, 2020 and November 8, 2022, inclusive? Did you lose money in your investment in GoodRx Holdings...
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Minnesota on behalf of all persons or entities who purchased or otherwise acquired GoodRx Holdings, In...
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings in the U.S., today announced it will release its first quarter 2024 financial results before U.S. markets open on Thursday, May 9, 2024. GoodRx manageme...
2024-04-10 14:00:03 ET Scott Schoenhaus from BOCOM International Holdings Company issued a price target of $9.00 for GDRX on 2024-04-10 12:10:00. The adjusted price target was set to $9.00. At the time of the announcement, GDRX was trading at $6.92. The overall price tar...
2024-04-10 12:56:01 ET More on Certara, GoodRx Holdings, etc. GoodRx Holdings: Large TAM Continues To Support Growth Health Catalyst: Achieving FY28 Long-Term Guidance Is Possible Voss Capital - R1 RCM Inc.: Bull Case Achievable Despite Negative Sentiment Wel...
2024-04-10 05:15:02 ET KeyBanc analyst issues OVERWEIGHT recommendation for GDRX on April 10, 2024 01:31AM ET. GDRX was trading at $6.74 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Strong Buy, 6 ...
2024-04-10 05:00:03 ET Scott Schoenhaus from KeyBanc issued a price target of $9.00 for GDRX on 2024-04-10 01:31:00. The adjusted price target was set to $9.00. At the time of the announcement, GDRX was trading at $6.74. The overall price target consensus is at $17.50 wi...
News, Short Squeeze, Breakout and More Instantly...
GoodRx Holdings Inc. Company Name:
GDRX Stock Symbol:
NASDAQ Market:
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings in the U.S., today announced it will hold its first Investor Day on May 15, 2024, in New York City. The event will begin at 9:00 a.m. Eastern Time (6:00...
LOS ANGELES, April 23, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Minnesota on behalf of all persons or entities who purchased or otherwise acquired GoodRx Holdings, In...